Thalia Therapeutics — Company Profile & Funding History

Product

The company’s portfolio includes miRisten, an investigational microRNA therapy for acute myeloid leukaemia, and a preclinical siRNA programme targeting cardiovascular risk.

Thalia also develops Nuvec, a nucleic-acid delivery platform. The business was formerly known as N4 Pharma.

Funding history

1 round · 1 with disclosed amounts

Announced	Round	Amount	Investors
Jun 24, 2026	Placing and subscription	£2.8M	Alastair Smith — ParticipantChris Britten — ParticipantDavid Solomon — ParticipantLuke Cairns — ParticipantMichael Palfreyman — ParticipantNorthern Standard Limited — ParticipantPremier Miton — Participant

Investors

Alastair SmithJoined Placing and subscription Chris BrittenJoined Placing and subscription David SolomonJoined Placing and subscription Luke CairnsJoined Placing and subscription Michael PalfreymanJoined Placing and subscription Northern Standard LimitedJoined Placing and subscription Premier MitonJoined Placing and subscription

Coverage

Jun 24, 2026Thalia Therapeutics · Placing and subscription

Similar companies

ALLOXALLOX combines high-throughput genetics, experimental biology and AI to find functional sites on proteins and develop targeted small-molecule medicines.$10.5M · Seed

Dren BioDren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.$350M · Private financing

BioGeometryBioGeometry develops generative AI models and experimental workflows for protein design, drug discovery and enzyme engineering.Undisclosed · Series A+

Sources

digitaljournal.com ↗